Keros Therapeutics (KROS) News
NASDAQ: KROSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.95+0.31 (+2.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
KROS news summary
We found 2 recent headlines mentioning Keros Therapeutics (KROS): 1 in the past week and 2 in the past 30 days, most often from Nasdaq. For price context, KROS is up 2.66% at $11.95. The most recent story, "Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?", was published by Nasdaq on Oct 7, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Keros Therapeutics headlines
- Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.NasdaqBMY, GERN, KROS
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.NasdaqKROS, REGN, TAK, PGEN